COMMUNIQUÉS West-GlobeNewswire

Considering MEDVi QUAD in 2026? Read This Before Enrolling in Any Compounded ED Telehealth Program
26/02/2026
An informational overview of publicly available disclosures, regulatory context, and verification steps consumers commonly review before starting compounded erectile dysfunction treatment through telehealth. NEWARK, DE [...]
Considering MEDVi Tirzepatide GLP-1 Weight Loss in 2026? Read This Before Enrolling in Any Tirzepatide GLP-1 Telehealth Weight Loss Program
26/02/2026
An independent informational overview of MEDVi's compounded tirzepatide telehealth program, including regulatory classification, platform structure, pricing disclosures, and key consumer verification steps. NEWARK, DE, [...]
MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001
26/02/2026
SHANGHAI, China, Feb. 25, 2026 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III [...]
Palvella Therapeutics Announces Pricing of Upsized Public Offering
26/02/2026
WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Sprout Health GLP-1 Weight Loss in 2026 — Compounded Semaglutide Pricing, FDA Status, and What To Know Before Starting a Telehealth GLP-1 Program
26/02/2026
An Independent Informational Overview Examining Sprout Health's Compounded GLP-1 Telehealth Model, Semaglutide and Tirzepatide Program Costs, FDA Regulatory Classification, and Consumer Verification Considerations for [...]
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
26/02/2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
25/02/2026
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income ( 1) of $161 Million, [...]
Premier Health Reports 2026 First Quarter Results
25/02/2026
MONTRÉAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSX-V: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]
Pennant Reports Fourth Quarter and Fiscal Year 2025 Results
25/02/2026
Conference Call and Webcast scheduled for tomorrow, February 26, 2026 at 10:00 am MT EAGLE, Idaho, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
Chemed Reports Fourth-Quarter 2025 Results
25/02/2026
CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation [...]
LifeStance Health Group Announces Launch of Secondary Public Offering
25/02/2026
SCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]
Informations sur le nombre total de droits de vote et d'actions
25/02/2026
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 25 février 2026, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
25/02/2026
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE ® ( [...]
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
25/02/2026
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be [...]
Korro to Present at the TD Cowen 46th Annual Health Care Conference
25/02/2026
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent [...]
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
25/02/2026
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
25/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Information on the total number of voting rights and shares
25/02/2026
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on [...]
NANOBIOTIX participera à plusieurs conférences investisseurs en mars
25/02/2026
PARIS et CAMBRIDGE, Mass., 25 févr. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]

Pages